Shed's structure is refreshingly readable: a flat $299 on a 28-day refill cycle, prepaid multi-month plans available, terms set out in the provider's own policy. There is nothing to decode, which is more than several options here manage.
The detail that matters most is the ceiling. Dosing is capped at 9 mg a week, so the upper half of the tirzepatide range is not available here. For some readers that will never be relevant. For others it settles the question on its own.
Here is how Shed reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Tirzepatide is titrated upward over months and people settle at very different effective doses. A 9 mg cap covers a good part of that range, but if you need more, continuing with Shed is not possible and you would be changing provider partway through — disruptive at exactly the point where continuity matters. This is published rather than buried, and it is the first thing to weigh.
Multi-month plans are prepaid and cancellation follows the provider's published policy. Those two facts deserve to be considered together rather than separately: committing several months ahead to a plan that may not reach the dose you need is a specific risk. Read both terms in one sitting before choosing a plan length.
Put these to Shed in writing, and keep the reply.
Shed rates low here because none of the whole-person rows are addressed and the cap narrows who it can serve over time. If you are settled at a lower dose and want simple flat pricing, it is clear and straightforward. Settle the ceiling question first.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.